The clinical benefit group (PR and SD) demonstrated higher PD-L1 expression in tumor cells (mean = 57.7%, SD = 30.5) than the non-responder PD group (mean = 13.2%, SD = 25.4; p < 0.001, false discovery rate (FDR) = 0.023; Figure 4A). Here, CD274 is linked to neoplasm.